Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...

A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit ...

Trastuzumab deruxtecan demonstrated a higher objective response rate of 62.6% compared to 34.4% with chemotherapy. Approximately 85%-90% of HR-positive, HER2-negative cases had actionable HER2 ...

Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Herceptin SC? Herceptin SC contains the active ...

In the UK, intravenous trastuzumab is used mainly as part of the combination with Perjeta and chemotherapy in breast cancer, and in metastatic gastric cancer. It will be in these indications where ...

Q-TWiST analysis of pembrolizumab plus trastuzumab and chemotherapy for patients with metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in the KEYNOTE-811 trial.

Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...

In contrast, Herceptin/Perjeta administration needs ... Phesgo has been recommended by the CHMP for use in combination with chemotherapy in early HER2-positive breast cancer – pre- and post ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...